| A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for reactivation from other “shock” drugs E Abner, M Stoszko, L Zeng, HC Chen, A Izquierdo-Bouldstridge, ... Journal of Virology 92 (10), 10.1128/jvi. 02056-17, 2018 | 52 | 2018 |
| Small molecule targeting of specific BAF (mSWI/SNF) complexes for HIV latency reversal CA Marian, M Stoszko, L Wang, MW Leighty, E de Crignis, CA Maschinot, ... Cell chemical biology 25 (12), 1443-1455. e14, 2018 | 43 | 2018 |
| Small molecule inhibitors of BAF; a promising family of compounds in HIV-1 latency reversal M Stoszko, E De Crignis, C Rokx, MM Khalid, C Lungu, RJ Palstra, ... EBioMedicine 3, 108-121, 2016 | 42 | 2016 |
| Arteriogenic therapy based on simultaneous delivery of VEGF-A and FGF4 genes improves the recovery from acute limb ischemia A Jazwa, M Tomczyk, HM Taha, E Hytonen, M Stoszko, L Zentilin, ... Vascular cell 5, 1-11, 2013 | 27 | 2013 |
| A broad drug arsenal to attack a strenuous latent HIV reservoir M Stoszko, E Ne, E Abner, T Mahmoudi Current Opinion in Virology 38, 37-53, 2019 | 23 | 2019 |
| HIF-regulated HO-1 gene transfer improves the post-ischemic limb recovery and diminishes TLR-triggered immune responses—effects modified by concomitant VEGF overexpression A Jazwa, M Stoszko, M Tomczyk, K Bukowska-Strakova, C Pichon, ... Vascular Pharmacology 71, 127-138, 2015 | 21 | 2015 |
| Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency M Stoszko, AMS Al-Hatmi, A Skriba, M Roling, E Ne, R Crespo, ... Science advances 6 (33), eaba6617, 2020 | 14 | 2020 |
| A two-color haploid genetic screen identifies novel host factors involved in HIV-1 latency M Röling, M Mollapour Sisakht, E Ne, P Moulos, R Crespo, M Stoszko, ... Mbio 12 (6), e02980-21, 2021 | 4 | 2021 |
| Molecular mechanisms controlling HIV transcription and latency–implications for therapeutic viral reactivation MD Röling, M Stoszko, T Mahmoudi Advances in Molecular Retrovirology. InTech, 45-105, 2016 | 4 | 2016 |
| The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy HAB Prins, R Crespo, C Lungu, S Rao, L Li, RJ Overmars, ... Science Advances 9 (11), eade6675, 2023 | 3 | 2023 |
| Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors W Schönemann, A Ludwig-Słomczyńska, Ł Dudek, M Król, M Farinone, ... Cancer Research 84 (6_Supplement), 5942-5942, 2024 | | 2024 |
| Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers A Radzimierski, A Bobowska, A Stachowicz, K Kuś, ... Cancer Research 84 (6_Supplement), 4598-4598, 2024 | | 2024 |
| Solving a BAF'ling Problem: pharmacological Reversal of HIV-1 Latency M Stoszko | | 2019 |
| Validation of an unbiased screen method for the identification of secondary fungal metabolites reversing HIV-1 latency M Stoszko, M Röling, E De Crignis, TW Kan, AMS Al-Hatmi, M Sulc, ... Journal of Virus Eradication 3, 5, 2017 | | 2017 |
| 38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal E De Crignis, M Stoszko, C Rokx, MM Khalid, C Lungu, RJ Palstra, ... | | 2016 |
| Molecular changes and gene therapy of the infarcted myocardium A Jazwa, M Tomczyk, M Stoszko, A Jozkowicz, J Dulak HUMAN GENE THERAPY 24 (12), A111-A112, 2013 | | 2013 |
| Gliotoxin, identified from a screen of Aspergillus fumigatus metabolites, reverses HIV-1 latency via release of P-TEFb M Stoszko, AMS Al-Hatmi, A Skriba, M Roling, YM Mueller, E Ne, ... Solving a BAF’ling problem. Pharmacological reversal of HIV-1 latency., 201, 0 | | |
